Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

HOLON,Israel,Aug. 28, 2025/PRNewswire/ --Compugen Ltd.(Nasdaq:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today announced that management will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference.

The fireside chat will be available on demand on the Investor Relations section of Compugen'swebsiteatwww.cgen.comfromFriday, September 5, 2025, 7:00 AM ET for 90 days.

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered inIsrael, with offices inSan Francisco, CA.Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

SOURCE Compugen Ltd.